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INTRODUCTION
Transforming growth factor (TGF)- is usually secreted
as a biologically inactive large latent TGF- complex (1-3).
The latent form of TGF- is composed of three elements, i.e.,
the mature TGF- , the latency-associated propeptide (LAP)
and the latent TGF- -binding protein (LTBP) (2, 4-6).
During secretion, TGF- is cleaved from its carboxy-ter-
minal LAP (7), which remains non-covalently bound to the
mature TGF- conferring latency to the complex (8). In the
large latent complex TGF- is attached by disulfide bond-
ing of its LAP-part to a high molecular weight LTBP (9, 10).
LTBP was first cloned in 1990 (6) and later renamed LTBP-1.
Three other LTBP isoforms (LTBPs-2, -3 and -4) have been
cloned since.
LTBP is required for the assembly and secretion of latent
TGF- (11) and also contribute to the matrix association (12)
and activation (13) of latent TGF- complex. The major frac-
tion (>90%) of secreted LTBP does not contain TGF- (3,
11, 12) and thus LTBP evidently possesses separate roles in
vivo as structural proteins of extracellular matrix (ECM) and
as TGF- targeting molecules (12, 14). Human LTBPs-1, -2,
and -4 have more than one alternative N-terminal region (5, 6,
15, 16). LTBP-1 appears as two mRNA species in Northern
blots. These mRNAs encode for two different N-terminal
variants, the longer LTBP-1L and the shorter LTBP-1S iso-
forms (5, 6). Independent promoters regulate the expression
of LTBP-1L and LTBP-1S in a cell type-specific manner (17).
LTBP-1L was found to interact more efficiently with ECM
(16) suggesting the importance of the N-termini of LTBP in
the ECM association. LTBP-1L is mainly expressed in heart,
placenta, kidney, and prostate, whereas LTBP-1S has a wider
expression pattern and appears also in the lung, skeletal mus-
cle, testis, and ovary (16). The existence of four LTBP isoforms,
their various alternatively spliced forms, and diverse mRNA
expression patterns in different tissues and developmental
stages suggest a substantial variety of functional properties
for LTBP.
Human liver myofibroblasts express transcripts of all three
TGF- isoforms, all four LTBP isoforms, and nearly all splice
variants of LTBP-1 and -4 suggesting that LTBP modulates
the bioactivity of TGF- in the diseased liver (18). LTBP-1
expression is co-regulated with TGF- 1 (11, 12, 19). LTBP-
1 expression is under the regulation of retinoic acid and cor-
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Expression and Regulation of Latent TGF- Binding Protein-1 
Transcripts and Their Splice Variants in Human Glomerular 
Endothelial Cells
Latent transforming growth factor (TGF)- -binding protein (LTBP) is required for the
assembly, secretion, matrix association, and activation of latent TGF- complex. To
elucidate the cell specific expression of the genes of LTBP-1 and their splice variants
and the factors that regulate the gene expression, we cultured primary human glo-
merular endothelial cells (HGEC) under different conditions. Basal expression of
LTBP-1 mRNA was suppressed in HGEC compared to WI-38 human embryonic
lung fibroblasts. High glucose, H2O2, and TGF- 1 upregulated and vascular endothe-
lial growth factor (VEGF) further downregulated LTBP-1 mRNA in HGEC. RT-PCR
with a primer set for LTBP-1S produced many clones but no clone was gained with
a primer set for LTBP-1L. Of 12 clones selected randomly, Sca I mapping and DNA
sequencing revealed that only one was LTBP-1S and all the others were LTBP-
1S 53. TGF- 1, but not high glucose, H2O2 or VEGF, tended to increase LTBP-
1S 53 mRNA. In conclusion, HGEC express LTBP-1 mRNA which is suppressed
at basal state but upregulated by high glucose, H2O2, and TGF- 1 and downregu-
lated by VEGF. Major splice variant of LTBP-1 in HGEC was LTBP-1S 53. Modi-
fication of LTBP-1S 53 gene in HGEC may abrogate fibrotic action of TGF- 1 but
this requires confirmation.
Key Words : Latent TGF-beta binding protein; Splice Variant of LTBP-1; Endothelial Cells; Trnasforming growth
factor beta1; Blood Glucose; Hydrogen Peroxide; Vascular Endothelial Growth Factor
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ticoids in normal and SV-40 virus-transformed human lung
fibroblasts (19). Basal expression levels of LTBP-1 were sig-
nificantly reduced in the transformed cells. TGF- 1 increased
its own expression as well as LTBP-1 levels in both cell lines
but the response was clearly of lower magnitude in transformed
cells (19).
Anomalous expression of LTBP may be associated with
human diseases. Overexpression of LTBP-1 was observed in
IgA nephropathy (20), chronic C hepatitis (21), idiopathic
pulmonary fibrosis (22), human capsular opacification (23),
and ovarian carcinoma (24). 
TGF- 1is a potent regulator of ECM synthesis and degra-
dation and is the key mediator of tissue fibrosis (25). Progres-
sive fibrosis in the kidney, liver, lung, heart, bone marrow,
skin, and lens is both the major cause of suffering and death
and an enormous burden to cost of health care (25). Renal
ablation induces glomerular endothelial as well as mesangial
cells to express TGF- 1 and matrix protein mRNAs leading
to glomerular fibrosis (26). TGF- 1 expression is increased
in diabetic kidney in experimental animals (27, 28) and in
humans (28). High glucose stimulates TGF- 1 mRNA and
protein expression in cultured glomerular mesangial cells (29),
glomerular epithelial cells (30), and proximal tubular epithe-
lial cells (31). High glucose-induced fibronectin upregulation
in glomerular mesangial cells is mediated by TGF- 1 (29). 
Blocking the secretion and activation of latent TGF- com-
plex through modification of LTBP gene may be one way of
preventing TGF- 1-induced tissue fibrosis. Little is known,
however, about the regulation of LTBP gene expression or
differential expression of LTBP isoforms and their alternatively
spliced forms in the kidney.
We, therefore, examined the basal expression of LTBP-1
and factors that regulate the expression of LTBP-1 transcripts
and their splice variants in human glomerular endothelial cells.
MATERIALS AND METHODS
Taq DNA polymerase, other restriction enzymes and dual
luciferase assay system were purchased from Promega (Promega
Corporation, Madison, WI, U.S.A.). 
Isolation and culture of human glomerular endothelial cell
(HGEC)
HGEC was isolated from the kidney removed from a Korean
patient with renal carcinoma. An informed consent was ob-
tained from the patient for experimental use of the kidney
tissue. Isolation, culture, and characterization of HGEC were
carried out according to the methods of Green et al. (32) and
Park et al. (33). In brief, cortex from apparently normal part
of the kidney was excised just after removal of the kidney and
then glomeruli were isolated using sieves. Glomeruli isolat-
ed were incubated at 37℃ in Dulbecco’s modified Eagle’s
medium (DMEM GIBCO BRL; Grand Island, NY, U.S.A.)
containing 20% of fetal bovine serum (FBS GIBCO BRL),
penicillin G (100 U/mL GIBCO BRL) and streptomycin (100
g/mL GIBCO BRL). Cells from out growth of glomeruli show-
ing cobblestone morphology and capillary-like tubule forma-
tion were selected as candidates for HGEC using cloning
cylinder. The colonies were amplified in 60-mm culture dish
with the same media. Immunofluoresence staining for Fac-
tor VIII was carried out for the confirmation of HGEC. Cells
from passage 4-7 were used for this study. To analyze the
expression of LTBP-1, the cells were cultured in DMEM con-
taining 20% of FBS, penicillin G (100 U/mL) and strepto-
mycin (100  g/mL). Before each experiment, the cells were
synchronized by serum-starvation in DMEM without FBS
for 24 hr. The cells were treated with DMEM containing
30 mM glucose (high glucose), 100  M H2O2, 2.5 ng/mL
of TGF- 1 (R&D System, Minneapolis, MN, U.S.A.) or 10
ng/mL of VEGF (R&D System) and incubated for 12 hr or
24 hr. Cells treated with DMEM containing 5.6 mM glucose
served as control. Cells were also treated with mannitol 25
mM added to media containing 5.6 mM glucose as an osmotic
control. The dosage of glucose, H2O2, TGF- , and VEGF
used in this study was based upon published reports from
our own laboratory and others.
Evaluation of LTBP-1 expression
To evaluate the total expression level of LTBP-1 mRNAs
including LTBP-1L, LTBP-1S and LTBP-1S 53, RT-PCR
was carried out with primers (LSF3 and LSR1 in Table 1)
whose sequences are found commonly at the 3′ end of all LTBP-
1 mRNAs (Fig. 1). PCR was carried out with an initial denat-
uration at 95℃for 3 min and then cycled 30 or 40 times for
one min at 95℃, followed by one min at 60℃ and 2 min
at 72℃. Then the reaction was maintained at 72℃ for an
additional 5 min before completion. As a control, human  -
actin was amplified by RT-PCR with primers (HBAF and
HBAR in Table 1) under the same condition. In addition,
Northern blot analysis was carried out to confirm the RT-
PCR result. The PCR product (1,040 bp) was labeled with
[- 32P] dCTP and used as probe.
Transient transfection assay
To compare the expression level of LTBP-1S of HGEC
with that of WI-38 lung fibroblasts (American Type Culture
Collection Rockville, MD, U.S.A.), transient transfection
assay was carried out with luciferase reporter construct, L-1S
PROM (a gift of Dr. Keski-Oja, 17). HGEC and WI-38 cells
were cultured in 60-mm diameter culture plates. At 60%
confluency, cells were co-transfected with 3  g L-1S PROM
and pRL-CMV control plasmid (Promega) containing Renilla
luciferase gene using GenePORTER2 transfection reagent
according to the manufacturer’s instruction (Gene Therapy630 J.H. Kwak, J.S. Woo, K. Shin, et al.
System, Telesis Court, San Diego, CA, U.S.A.). Four hours
after transfection, the media were changed with the same
fresh media, and incubated for another 24 hr. The cells were
washed twice with phosphate-buffered saline (PBS) and lysed
with 500  L of Passive Lysis Buffer in Dual Luciferase kit
(Promega Corp., Madison, WI, U.S.A.). The luciferase activity
of the lysate was measured by using TD-20/20 luminometer
(Tunner Designs, Sunnyvale, CA, U.S.A.).
Synthesis of the first stranded cDNA and cloning of LTBP-
1 gene
Total RNA was isolated from cultured HGEC or WI-38
with TRI RAGENT (Molecular Research Center, Cincinati,
OH, U.S.A.), and the first stranded cDNA was synthesized
by AMV reverse transcriptase (Promega Corporation, Madi-
son, WI, U.S.A.) using oligo dT15 primer with 3  g of total
RNA. For the amplification of the LTBP-1 genes, two differ-
ent sets of PCR primers (LF1/LSR1 and SF1/LSR1) were
designed according to the DNA sequences from GenBank
(M34057 and L48925) as shown in Table 1. For the PCR
amplification of LTBP-1L and LTBP-1S, 20 pmol of each
primer set was used. PCR was carried out with an initial denat-
uration at 95℃ for 3 min and then was cycled 30 times for
one min at 95℃, followed by one min at 50℃ and 8 min
at 72℃. Then the reaction was maintained at 72℃ for an
additional 15 min before completion. The PCR products
were cloned directly on PCR 2.1-TOPO TA cloning vector
(Invitrogen Corp., Carlsbad, CA, U.S.A.). To confirm that
the PCR product was LTBP-1 gene, nucleotide sequences of
the clones were determined using a BigDyeTM-terminator
kit (Perkin-Elmer, Wellesley, MA, U.S.A.) and analyzed with
ABI 310 genetic analyzer (Applied Biosystem Inc, Foster
City, CA, U.S.A.).
Identification of LTBP-1S and LTBP-1S 53 mRNA
To distinguish the mRNA of LTBP-1S 53 from that of
LTBP-1S, RT-PCR was carried out with internal primers
(LSF2 and LSR2 in Table 1) prepared according to the sequences
found near up-stream and down-stream of the deleted region
of LTBP-1S 53. With the primer set, LTBP-1S mRNA will
give 469 bp PCR product while 310 bp PCR product will
be amplified from LTBP-1S 53. PCR was carried out with
an initial denaturation at 95℃ for 3 min and then was cycled
30 or 40 times for one min at 95℃, followed by one min at
55℃ and 2 min at 72℃. Then the reaction was maintained
at 72℃ for an additional 5 min before completion. One fifth
of the PCR product was electrophoresed on 1.5% agarose gel.
Data analysis
All results are expressed as mean±standard error (SE). Anal-
ysis of variance (ANOVA) was used to assess the difference
between multiple groups. If the F statistics was significant,
the mean values obtained from each group were then com-
pared by Fisher’s least significant difference method. P value
<0.05 was used as the criterion for a statistically significant
469 bp (1S) or 310 bp ( 53)
SF1 LSF2 LSR2 LSF3 LSR1
Total LTBP: 1040 bp
HRRRPIHHHVGK
8-Cys repeat Hybrid type 8-Cys repeat
53 region
RGD sequence
Ca
2+ binding EGF-like repeat
Non-Ca
2+ binding EGF-like repeat
Glycosylation site
ECM binding
TGF- binding
LTBP-1S 53:
Fig. 1. Structural features of LTBP-1S and LTBP-1S 53. Simple structural features of LTBP-1S, primer sets, the size of PCR products and
the deleted region in LTBP-1S 53 are shown. A putative heparin-binding site is shown by amino acid sequence (HRRRPIHHHVGK) and
other typical motifs, repeats and sites are illustrated with various symbols.
The expecting sizes of PCR products by using the primer sets are as
follows; 5.2 kb by LF1/LSR1, 4.2 kb by SF1/LSR1, 469 bp or 310 bp by
LSF2/LSR2, 1 kb by LSF3/LSR1 and 539 bp by HBAF/HBAR.
Primer name Primer sequence (5′ to 3′ )
LF1 ATGGCGGGGGCCTGGCTCAGGT
LSR1 CTCCAGGTCACTGTCTTTCTCTAA
SF1 ACCATGGATACTAAGCTGATGTGTTTG
LSF2 CCATGGGCAGCTATCGATGTACC
LSR2 TGCAGTTGCCACTTCTGGCTCCGC
LSF3 GGGATGGGGAGATAACTG
HBAF GTGGGGCGCCCCAGGCACCA
HBAR CTCCTTAATGTCACGCACGATTTC
Table 1. Nucleotide sequences of the primers used in this studyExpression of LTBP-1 Transcripts in HGEC 631
difference.
RESULTS
Basal expression of LTBP-1 in HGEC
To evaluate the cell type-specific expression of LTBP-1, RT-
PCR was carried out with total RNA from cultured HGEC
and WI-38 lung fibroblasts. PCR product was easily detected
on the agarose gel after 30-cycle reaction with total RNA of
WI-38. Similar amount of PCR product from total RNA of
HGEC was recognized when the PCR was performed 40 cycles.
The expression level of LTBP-1 in HGEC was much lower
than that in WI-38. The RT-PCR result was supported by
Northern blot analysis as well as by transient transfection assay.
As shown in Fig. 2A, two LTBP-1 transcripts (7.0 kb for LTBP-
1L and 5.2 kb for LTBP-1S) were detected from total RNA
of WI-38, whereas no signals were obtained from HGEC. In
addition, when L-1S PROM was introduced into cells, luci-
ferase was hardly expressed in HGEC but very strong luciferase
activity was measured in the extract of WI-38 (Fig. 2B). 
Effect of high glucose, H2O2, TGF- and VEGF on LTBP-
1 mRNA expression in HGEC
As shown in Fig. 3, high glucose, H2O2, and TGF- 1 in-
creased LTBP-1 mRNA expression by 1.2 (±0.2), 1.6 (±
0.3) and 1.3 (±0.2) folds that of control, respectively, at 12 hr
after treatment. High glucose and TGF- 1 but not H2O2,
further increased LTBP-1 expression to 1.5 (±0.3) and 1.8
(±0.3) folds, respectively, at 24 hr. Mannitol 25 mM added
to media containing 5.6 mM glucose failed to increase LTBP-
1 mRNA (data not shown). On the contrary, VEGF suppressed
LTBP-1 expression to 80% of control at 12 hr and to 60% at
24 hr.
Cloning and characterization of LTBP-1 gene
To obtain the respective LTBP-1L and LTBP-1S clone, two
different PCR primer sets (LF1/LSR1and SF1/LSR1) were
used for RT-PCR and the PCR products were analyzed on
1% agarose gel electrophoresis. In the case of LTBP-1S, about
4.2 kb DNA fragment was observed whereas there was no
detectable PCR product for LTBP-1L (data not shown). The
PCR products were cloned by using PCR 2.1-TOPO TA
cloning system, and then introduced into E. coli Top10F’.
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Fig. 2. Estimation of basal LTBP-1 expression in HGEC. Northern
blot analysis for LTBP-1 expression was carried out with RNA from
HGEC and WI-38. The results of three independent experiments
are presented. 28S and 18S served as internal controls (A). (B)
Transient transfection assay for LTBP-1 expression was carried
out with L-1S PROM, a reporter construct covering the 1,751 bp
upstream region of LTBP-1S gene. The reporter construct was
introduced with pRL-CMV into HGEC and WI-38 and cell lysate
of each culture was prepared after 24 hr of transfection. The mean
value of the activity from three independent experiments is shown
with the value of WI-38 as 100%.
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Fig. 3. Expression patterns of LTBP-1 in HGEC cultured under dif-
ferent conditions. The first stranded cDNA was synthesized with
3  g of total RNA from HGEC and then PCR with primers (LSF3
and LSR1) was carried out 40 cycles. For standardization of the
amount of the respective RNA applied,  -actin was amplified with
the same cDNA prepared. One fifth of PCR volume was applied
on the 1.5% agarose gel electrophoresis. The results of five inde-
pendent experiments are shown as fold change relative to control
(B). Upper panel (A) is a representative bands of PCR products
from 5 experiments. C: control; HG: high glucose (30 mM); H2O2:
100 M H2O2; TGF- 1: 2.5 ng/mL of TGF- 1; VEGF: 10 ng/mL of
VEGF; M: molecular size marker; *p<0.05 compared to 12 hr control.
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After transformation, the bacterial cells were cultured on LB
agar plate supplemented with 100  g/mL of ampicillin and
5-bromo-4-chloro-3-indolyl- -galactopyranoside. Some white
colonies were grown on the plate when PCR product of LTBP-
1S was applied. However, no transformant was grown on the
same agar media when PCR product of LTBP-1L was em-
ployed. Twenty recombinant plasmids were isolated randomly,
and PCR was carried out with the same primers (SF1/LSR1)
to identify the insert on the cloning vector. Twelve recombi-
nant plasmids tested yielded the 4.2 kb PCR products and
nucleotide sequences of the two clones selected randomly
were determined. The DNA sequences revealed that both
clones were LTBP-1S 53, an alternative spliced-form of
LTBP-1S. 
Identification of LTBP-1S and LTBP-1S 53 clone
To confirm that the other 10 clones were either LTBP-1S
or LTBP-1S 53, the recombinant plasmids obtained were
digested with Sca I. The Sca I site is unique in LTBP-1S and
does not exist in LTBP-1S 53 since the restriction site is
located in the deleted region of LTBP-1S 53. PCR 2.1-
TOPO TA cloning vector also possesses one Sca I site, there-
fore, LTBP-1S clone possesses two Sca I sites whereas LTBP-
1S 53 has only one. As shown in Fig. 4, only one clone was
a candidate for LTBP-1S (lane 12) and the others were all for
LTBP-1S 53. The candidate clone for LTBP-1S was con-
firmed as LTBP-1S by determination of its DNA sequence.
The DNA and deduced amino acid sequences of newly cloned
LTBP-1S deposited to GenBank (accession No. AF489528)
were compared to LTBP-1S sequence from GenBank data
bases (accession No. M34057). The new LTBP-1S clone from
Korea has four different nucleotides (1093T→C; 1510G→
A; 3498T→G; 4000T→G), and three of them change amino
acid (365 Tyr→His; 604 Val→Thr; 1334 Phe→Val). The
first nucleotide of start codon is 1, and the nucleotides show-
ing after numbers are found in the sequences of M34057.
Determination of the major splice variant of LTBP-1 RNA
in HGEC
To confirm that LTBP-1S 53 is the major splice variant
of LTBP-1 transcript in HGEC, the transcript was analyzed
by RT-PCR with internal primer set (LSF2 and LSR2). The
expecting size of RT-PCR product was 469 bp for LTBP-1S
and 310 bp for LTBP-1S 53. As a control, total RNA from
WI-38 was subjected to RT-PCR with the same condition.
Three different-sized PCR products, 310 bp, 469 bp and an
unexpected 620 bp were produced from total RNA of WI-
Fig. 5. Alternative spliced-form of LTBP-1 RNA in HGEC and WI-
38. The first stranded cDNA was synthesized with 3  g of total
RNA from HGEC and WI-38. PCR with internal primers (LSF2 and
LSR2) was carried out 30 cycles for WI-38 (lane 1) and 40 cycles
for HGEC (lane 2 and 3). For standardization of the amount of
respective RNA applied,  -actin was amplified with 30 cycles of
PCR with the same cDNA prepared. One fifth of PCR volume was
applied on the 1.5% agarose gel electrophoresis.
Fig. 4. Identification of LTBP-1S and LTBP-1S 5 by restriction
mapping. Restriction mapping with Sca I (Promega) was carried out
to screen the candidate clones for LTBP-1S. Two Sca I sites are in
LTBP-1S (lane 12), but only one site in LTBP-1S 53 (lane 1-11).
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Fig. 6. Changes of the splicing pattern in HGEC cultured under
different conditions. RT-PCR was done with the same method de-
scribed in Fig. 5. Upper panel (A) is a representative bands for
LTBP-1S and LTBP-1S 53 under different stimuli from PCR prod-
ucts from 5 independent experiments. Lower panel (B) shows the
mean±SE of LTBP-1S 53/LTBP-1S ratio from 5 experiments. C:
control; HG: high (30 mM) glucose; H2O2: 100  M H2O2; TGF-
1: 2.5 ng/mL of TGF- 1; VEGF: 10 ng/mL of VEGF; M: molecular
size marker.
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38 (Fig. 5). Two smaller products were eluted from agarose
gel and cloned on PCR 2.1-TOPO TA cloning vector. DNA
sequences were determined and those DNA fragments were
confirmed as a part of LTBP-1S 53 and LTBP-1S as expect-
ed (data not shown). The splicing pattern of LTBP-1 was
different between WI-38 and HGEC. In the case of WI-38,
469 bp PCR product was found as the major form. In HGEC,
however, 310 bp PCR product was the major form and all
PCR product was LTBP-1S 53 in some case (Fig. 5). The
results from cDNA cloning, Sca I mapping, and RT-PCR
with internal primers indicated that the major splice variant
of LTBP-1 is LTBP-1S 53 in HGEC.
TGF- 1 alters the splicing of LTBP-1S transcript
As shown in Fig. 6, high glucose or H2O2 did not change
the ratio of LTBP-1S 53/LTBP-1S at 12 and 24 after treat-
ment. TGF- 1 increased the LTBP-1S 53 mRNA and the
LTBP-1S 53/LTBP-1S ratio at 24 hr although the difference
did not reach statistical significance.
DISCUSSION
Chronic progressive renal disease is characterized by glomeru-
lar and tubulointerstitial fibrosis. TGF- 1 is a potent regu-
lator of ECM synthesis and degradation and is the key medi-
ator of renal fibrosis (25).
Renal ablation, an animal model of chronic renal failure,
induces glomerular endothelial as well as mesangial cells to
express TGF- 1 and ECM mRNAs leading to glomerular
fibrosis or glomerulosclerosis (26).
Diabetic nephropathy, the single most common cause of
endstage renal disease, is also characterized by overexpres-
sion of TGF- 1 and excessive accumulation of ECM in the
kidney. High glucose upregulates TGF- 1 and ECM genes
and proteins in glomerular mesangial and tubular epithelial
cells and in diabetic kidney (34). Antioxidants inhibit high
glucose-induced TGF- 1 and ECM expression in renal cells
and ameliorate features of diabetic nephropathy suggesting
that reactive oxygen species mediate high glucose-induced
TGF- 1 and ECM expression (34).
Modification of LTBP gene may prevent secretion and acti-
vation of latent TGF- complex and abrogate fibrotic action
of TGF- 1. Little is known, however, about the regulation
of LTBP expression or differential expression of LTBP isoforms
and their splice variants in the kidney.
We, therefore, examined the basal expression of LTBP-1
transcripts and their splice variants in HGEC and the factors
that regulate LTBP-1 gene expression in HGEC. We found
that basal expression of LTBP-1 mRNA was suppressed in
HGEC as compared to WI-38, human embryonic lung fibrob-
lasts, that high glucose, H2O2, and TGF- 1 upregulated and
VEGF downregulated LTBP-1 expression, and that the major
splice variant of LTBP-1 was LTBP-1S 53. TGF- 1, but
not high glucose or H2O2, had a tendency to increase LTBP-
1S 53 mRNA.
The results from RT-PCR and transfection assay strongly
suggested that the basal expression of LTBP-1 is suppressed
in HGEC. LTBP-1S expression was less than 4% that of WI-
38 cells. It is possible that this suppression is related to the
background of HGEC used in this study. The cells were ob-
tained from a patient with renal cell carcinoma. Basal expres-
sion of LTBP-1 was significantly reduced in SV-40 virus-
transformed human lung fibroblasts compared to normal
lung fibroblasts (19). TGF- 1 increased LTBP-1 levels in
both cell lines, but the response was clearly of lower magni-
tude in transformed cells (19). This may reflect insensitivity
to TGF- 1, which is a common feature for malignant cells.
The mRNA level of LTBP-1 was decreased in neoplastic
parenchymal cells but increased in the ECM of hepatocellu-
lar and fibrolamellar carcinoma of the liver (35). Since TGF- 1
is known to be overexpressed in liver tumors, the results sug-
gest enhanced synthesis of TGF- 1 without binding to LTBP-
1 resulting in the decreased bioavailability of TGF- 1 in
tumor cells. On the other hand, this suppressed expression
of LTBP-1 mRNA may be a characteristic of glomerular
endothelial cells. This needs to be confirmed in glomerular
endothelial cells isolated from normal human kidney.
We found that high glucose, H2O2, and TGF- 1 upregu-
lated and VEGF downregulated LTBP-1 mRNA in HGEC.
High glucose and H2O2 upregulate TGF- 1 mRNA levels
in renal cells (34). TGF- 1 auto-regulates its own expression
(25). LTBP-1 plays a central role in secretion and activation
of latent TGF- complex and LTBP-1 expression is co-regulat-
ed with TGF- 1 (11, 12, 19). TGF- 1 upregulated mRNA
levels of both TGF- 1 and LTBP-1 in normal and transformed
human lung fibroblasts (19). The expression of LTBP-1
mRNA in lung fibroblasts was also upregulated by retinoic
acid and corticoids (19). The significance of downregulation
of LTBP-1 mRNA by VEGF in HGEC is not clear at this
time. Glomerular capillary endothelial cells express VEGF
receptor (36) and proliferate in response to VEGF. TGF-
induces VEGF expression in lung fibroblasts (37) and VEGF
attenuates actions of TGF- 1 in human endothelial cells (38).
It is possible that VEGF acts as an adaptive mechanism to
TGF- -induced upregulation of LTBP-1.
The present data suggest that the major form of splice vari-
ant of LTBP-1 in HGEC is LTBP-1S 53, a splice variant
of LTBP-1S, unlike in WI-38 lung fibroblasts where both
LTBP-1L and -1S were found. In SV-40 virus-transformed
WI-38 lung fibroblasts a regulatory element repressed the
transcription of LTBP-1S by a cell specific manner (17).
TGF- 1, but not high glucose or H2O2, had a tendency to
upregulate LTBP-1S 53 mRNA and the LTBP-1S 53/
LTBP-1S ratio in HGEC.
In conclusion, HGEC express LTBP-1 mRNA which is
suppressed at basal state but upregulated by high glucose,634 J.H. Kwak, J.S. Woo, K. Shin, et al.
H2O2, and TGF- 1 and further downregulated by VEGF.
The major splice variant of LTBP-1 in HGEC was LTBP-
1S 53 and the mRNA was upregulated by TGF- 1. It is
tempting to speculate that modification of LTBP-1S 53 gene
in HGEC may abrogate fibrotic action of TGF- 1. Future
studies are needed to demonstrate the effect of deletion or
mutation of LTBP-1S 53 gene in HGEC on TGF- 1 expres-
sion and the fibrotic action of TGF- 1.
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